FDA Approves First Software Offering from EOS Imaging

Paris, France-based EOS Imaging, which makes 2-D and 3-D imaging technology for orthopedic applications, has earned U.S. Food and Drug Administration (FDA) approval for HipEOS, a 3-D hip arthroplasty planning software based on EOS stereo-radiographic 2-D/3-D imaging.

HipEOS is the first offering of a software portfolio associated with the EOS imaging system. Developed by OneFit medical, an EOS imaging group company, the software is designed to allow surgeons to perform, pre-surgical planning including hip implant selection and virtual positioning in functional, weight-bearing 3-D. The software takes full advantage of the real size 3-D patient anatomical information obtained from the EOS exam to help physicians define implant size and visualize pre-operatively the restoration expected from a total hip arthroplasty prior to surgery. HipEOS received a CE mark in March 2014.

Hip arthroplasty is the first procedure EOS is targeting with planning software that uses its existing imaging technology. The company intends to expand the suite of offerings to include additional orthopedic surgery planning software.

The U.S. launch of the HipEOS software is planned for the American Academy of Orthopedic Surgeons Annual Meeting, this year to be held March 24-28 in Las Vegas, Nev. The software was launched in France in Novermber during the annual meeting of French Society of Orthopedic Surgery and Traumatology (SOFCOT).

“HipEOS is the first step of our strategy to fully utilize EOS’ unique stereo-radiographic 2-D/3-D patient data in software tools that will help surgeons plan and execute precise surgical and non surgical treatments,” said CEO Marie Meynadier. “We are very happy to have been granted market approval in the U.S. and to extend this offering, which has received a very positive feedback at the French SOFCOT launch in November, to our U.S. users and future users.”